Exodus Point Capital Management, LP Bluebird Bio, Inc. Transaction History

Exodus Point Capital Management, LP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$0.47 - $1.35 $609,433 - $1.75 Million	1,296,668 New	1,296,668 $674,000
Q3 2023 Nov 09, 2023	BUY	$3.02 - $4.05 $459,360 - $616,029	152,106 Added 56.0%	423,733 $1.29 Million
Q2 2023 Aug 10, 2023	BUY	$2.79 - $5.03 $757,839 - $1.37 Million	271,627 New	271,627 $894,000
Q4 2022 Feb 13, 2023	SELL	$5.77 - $8.49 $785,712 - $1.16 Million	-136,172 Reduced 56.02%	106,923 $740,000
Q3 2022 Nov 10, 2022	BUY	$3.75 - $7.39 $263,760 - $519,783	70,336 Added 40.71%	243,095 $1.54 Million
Q2 2022 Aug 19, 2022	BUY	$2.94 - $5.23 $305,319 - $543,135	103,850 Added 150.71%	172,759 $715,000
Q1 2022 May 13, 2022	BUY	$4.07 - $10.6 $280,459 - $730,435	68,909 New	68,909 $334,000
Q4 2021 Feb 11, 2022	SELL	$8.96 - $16.31 $735,911 - $1.34 Million	-82,133 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$11.24 - $21.0 $923,174 - $1.72 Million	82,133 New	82,133 $1.57 Million
Q4 2020 Feb 16, 2021	SELL	$27.5 - $37.92 $222,805 - $307,227	-8,102 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$34.44 - $43.75 $498,794 - $633,631	-14,483 Reduced 64.13%	8,102 $437,000
Q2 2020 Aug 14, 2020	BUY	$27.12 - $45.97 $612,505 - $1.04 Million	22,585 New	22,585 $1.38 Million
Q4 2019 Feb 14, 2020	SELL	$46.96 - $61.67 $206,624 - $271,348	-4,400 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$59.47 - $93.1 $42,461 - $66,473	714 Added 19.37%	4,400 $404,000
Q2 2019 Aug 14, 2019	BUY	$75.84 - $105.21 $279,546 - $387,804	3,686 New	3,686 $469,000

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $315M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.